FORMULATION AND EVALUATION OF FAST DISSOLVING TABLETS OF LISINOPRIL
Abstract
Objective: The current study's objective is to develop and evaluate Fast dissolving tablets (FDT) of Lisinopril. Lisinopril, an Angiotensin Converting Enzyme Inhibitor (ACEI), preventing the conversion of angiotensin I to angiotensin II. To improve patient compliance making convenience is crucial. hence an effort was made by formulating it as the fast dissolving tablet to reduce the water intake for chronic kidney patients suffered from hypertension.
Methods: Using various quantities of Vivasol & Explotab as Superdisintegrants, FDT formulations of Lisinopril were preared utilising the Direct Compression technique. Nine trials were developed and assessed for Pharmaceutical Product Performance.
Results: Findings indicate that all formulations meet the acceptance criteria, and kinetic modelling was applied to the in-vitro dissolution profiles.
Conclusion: The best formulation (F1) contained 5 mg of Vivasol and 5 mg of Explotab showed promising results for obtain quicker disintegration and may produce patient compliance by means of rapid onset of action and preventing first pas effect too. Formulation (F1) follow first order (r= 0.934), whereas release mechanism found to be fickian type (n= 0.267).
Downloads
All the articles published in JAPSR are distributed under a creative commons license (CC BY-NC-SA 4.0)
Under this license, you are free to:
- Share- copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt- remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Copyright policy
The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.
Licensing policy
The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.
